During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

Unlike current anti-VEGF agents that act extracellularly, TKIs target intracellular pathways, providing a complementary mechanism of action. Sustained-release TKI implants have demonstrated ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...

Sequential therapy with either continued VEGF receptor inhibition (tyrosine kinase inhibitor [TKI]-TKI sequence) or alternate pathway inhibition (TKI–mTOR sequence) results in prolonged disease ...

Adding the VEGF inhibitor ramucirumab (Cyramza ... addition of ramucirumab to osimertinib significantly prolongs PFS in TKI [tyrosine kinase inhibitor]-naive patients with NSCLC harboring ...

Standard-of-care options have long included VEGF-R TKI monotherapy or its combination with mammalian target of rapamycin and now also include the HIF-2α inhibitor, belzutifan. 19 However, patients in ...

The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be ...

The drug is also approved in the U.S. for the treatment of adults with advanced renal cell carcinoma following a PD-1/PD-L1 ...

Tip cell filopodia express high-affinity tyrosine kinase receptors for VEGF, which dimerize and autophosphorylate upon ligand binding. VEGF receptor activation promotes its internalization and the ...

Data from ongoing TKI studies show encouraging results in improving ... expert faculty summarize the challenges associated with anti-VEGF use, review the rationale for targeting tyrosine kinases ...